Table 5 Comparison of planned cumulative... | American Society of Hematology

Table 5

Comparison of planned cumulative drug doses during postremission therapy

	CCG 1882-BFM, n = 118	CCG 1882 A-BFM, n = 39	CALGB, n = 112
Dexamethasone, mg/m²	210	420	140
Vincristine, mg/m²	22.5	45	14 mg total
l-Asparaginase, U/m²	90 000	318 000	48 000
Doxorubicin, mg/m²	75	150	90
Cytarabine, mg/m²	1800	2400	1200*
Cyclophosphamide, mg/m²	3000	4000	3000
6-Thioguanine, mg/m²	840	1680	840
6-Mercaptopurine, mg/m²	4080	4080	5040
Methotrexate (IV or oral), mg/m²	90	1000	100†
Intrathecal methotrexate and cranial radiotherapy	132 mg + 1800 cGy or 216 mg + no radiotherapy	132 mg, 1800 cGy	105 mg‡, 2400 cGy

	CCG 1882-BFM, n = 118	CCG 1882 A-BFM, n = 39	CALGB, n = 112
Dexamethasone, mg/m²	210	420	140
Vincristine, mg/m²	22.5	45	14 mg total
l-Asparaginase, U/m²	90 000	318 000	48 000
Doxorubicin, mg/m²	75	150	90
Cytarabine, mg/m²	1800	2400	1200*
Cyclophosphamide, mg/m²	3000	4000	3000
6-Thioguanine, mg/m²	840	1680	840
6-Mercaptopurine, mg/m²	4080	4080	5040
Methotrexate (IV or oral), mg/m²	90	1000	100†
Intrathecal methotrexate and cranial radiotherapy	132 mg + 1800 cGy or 216 mg + no radiotherapy	132 mg, 1800 cGy	105 mg‡, 2400 cGy

In CALGB 19802, patients received a 10-fold higher cumulative dose of 12 000 mg/m² of cytarabine.

In CALGB 19802, patients received a total of 6600 mg/m² of systemic methotrexate.

In CALGB 19802, patients received a total of 120 mg of IT methotrexate; cranial irradiation was omitted.